Ensysce Biosciences Inc. (ENSC)
Ensysce Biosciences Inc. (ENSC) Stock Price, Analysis & Data
| Bid | 0.33 |
| Market Cap | 6.49M |
| Revenue (ttm) | 4.5M |
| Net Income (ttm) | -12.62M |
| Beta | n/a |
| EPS (ttm) | -3.11 |
| PE Ratio (ttm) | n/a |
| Forward PE | -8 |
| P/B (ttm) | -10.81 |
| P/S (ttm) | 1.44 |
| Earnings Date | Aug 14, 2025 |
| Ask | 0.53 |
| Volume | 17,115,585 |
| Avg. Volume (20D) | 14,803,080 |
| Open | 0.34 |
| Previous Close | 0.35 |
| Day's Range | 0.34 - 0.47 |
| 52-Week Range | 0.23 - 2.75 |
| Analyst | Strong Buy |
| Price Target | 8.25 (1962.50%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About ENSC
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, develops prescription drugs for severe pain relief in opioid misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection (TAAP) platform, designed to release clinically effective drugs only when exposed to specific physiological conditions; and Multi-Pill Abuse Resistance (MPAR) platform, an over-dose protection opioid prodrug t...
Financial Performance
In 2025, Ensysce Biosciences's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -10.18M, an increase of 27.4%.
Financial StatementsAnalyst Forecast
According to 1 analyst ratings, the average rating for ENSC stock is "Strong Buy". The 12-month stock price forecast is 8.25, which is upside of 1962.5% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
5 months ago · Associated Press Finance
BC-Most Active StocksElong Power Holding Ltd. 27,481,598 0.1358